Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 13;9:659294. doi: 10.3389/fcell.2021.659294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhou, Lu, Xun, Xu, Liu, Xia, Lu, Wang and Hu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Predictive value of ubiquitin score for immunotherapy and targeted therapies. (A,D,G) The predicted response rate in TIDE analysis of the discovery, testing, and external validating datasets. Fisher exact test, p = 0.003, p = 0.034, p = 3.71e-08, respectively. (B,E,H) Subclass mapping results indicated that the high score group was more likely to respond to anti-PD-1 treatment (Bonferroni corrected p-value = 0.004, 0.008, 0.001, respectively). (C,F,I) Boxplots of the estimated IC50 values for Sorafenib, Sunitinib, Pazopanib, and Axitinib in the three cohorts, Wilcoxon test.